pLenti6/V5-p53_wt p53 Citations (17)

Originally described in: Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells.
Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, Futscher BW Neoplasia. 2008 May . 10(5):450-61. PubMed

---

Articles Citing pLenti6/V5-p53_wt p53

Articles
P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance. Hashimoto A, Oikawa T, Hashimoto S, Sugino H, Yoshikawa A, Otsuka Y, Handa H, Onodera Y, Nam JM, Oneyama C, Okada M, Fukuda M, Sabe H. J Cell Biol. 2016 Apr 11;213(1):81-95. doi: 10.1083/jcb.201510002. Epub 2016 Apr 4. PubMed
A dual molecular analogue tuner for dissecting protein function in mammalian cells. Brosh R, Hrynyk I, Shen J, Waghray A, Zheng N, Lemischka IR. Nat Commun. 2016 May 27;7:11742. doi: 10.1038/ncomms11742. PubMed
ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistance. Hashimoto A, Hashimoto S, Sugino H, Yoshikawa A, Onodera Y, Handa H, Oikawa T, Sabe H. Oncogenesis. 2016 Sep 12;5(9):e259. doi: 10.1038/oncsis.2016.60. PubMed
CHK1 and RAD51 activation after DNA damage is regulated via urokinase receptor/TLR4 signaling. Narayanaswamy PB, Tkachuk S, Haller H, Dumler I, Kiyan Y. Cell Death Dis. 2016 Sep 29;7(9):e2383. doi: 10.1038/cddis.2016.291. PubMed
Cancer cell-secreted IGF2 instigates fibroblasts and bone marrow-derived vascular progenitor cells to promote cancer progression. Xu WW, Li B, Guan XY, Chung SK, Wang Y, Yip YL, Law SY, Chan KT, Lee NP, Chan KW, Xu LY, Li EM, Tsao SW, He QY, Cheung AL. Nat Commun. 2017 Feb 10;8:14399. doi: 10.1038/ncomms14399. PubMed
p53 modulates the effect of ribosomal protein S6 kinase1 (S6K1) on cisplatin toxicity in chronic myeloid leukemia cells. Xiao LY, Kan WM. Pharmacol Res. 2017 May;119:443-462. doi: 10.1016/j.phrs.2017.03.004. Epub 2017 Mar 14. PubMed
Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding. Liao P, Zeng SX, Zhou X, Chen T, Zhou F, Cao B, Jung JH, Del Sal G, Luo S, Lu H. Mol Cell. 2017 Dec 21;68(6):1134-1146.e6. doi: 10.1016/j.molcel.2017.11.006. Epub 2017 Dec 7. PubMed
A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness. di Gennaro A, Damiano V, Brisotto G, Armellin M, Perin T, Zucchetto A, Guardascione M, Spaink HP, Doglioni C, Snaar-Jagalska BE, Santarosa M, Maestro R. Cell Death Differ. 2018 Dec;25(12):2165-2180. doi: 10.1038/s41418-018-0103-x. Epub 2018 Apr 17. PubMed
Tolerance to sustained activation of the cAMP/Creb pathway activity in osteoblastic cells is enabled by loss of p53. Walia MK, Taylor S, Ho PWM, Martin TJ, Walkley CR. Cell Death Dis. 2018 Aug 28;9(9):844. doi: 10.1038/s41419-018-0944-8. PubMed
Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers. Goswami MT, VanDenBerg KR, Han S, Wang LL, Singh B, Weiss T, Barlow M, Kamberov S, Wilder-Romans K, Rhodes DR, Feng FY, Tomlins SA. Mol Cancer Res. 2019 Aug;17(8):1652-1664. doi: 10.1158/1541-7786.MCR-19-0144. Epub 2019 May 20. PubMed
Wild-type TP53 defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCs. Zhang C, Martinez-Ledesma E, Gao F, Zhang W, Ding J, Wu S, Li X, Wu J, Yuan Y, Koul D, Alfred Yung WK. Am J Cancer Res. 2019 Aug 1;9(8):1734-1745. eCollection 2019. PubMed
Mutant p53 elicits context-dependent pro-tumorigenic phenotypes. McCann JJ, Vasilevskaya IA, McNair C, Gallagher P, Neupane NP, de Leeuw R, Shafi AA, Dylgjeri E, Mandigo AC, Schiewer MJ, Knudsen KE. Oncogene. 2022 Jan;41(3):444-458. doi: 10.1038/s41388-021-01903-5. Epub 2021 Nov 12. PubMed
Histone N-terminal acetyltransferase NAA40 links one-carbon metabolism to chemoresistance. Demetriadou C, Raoukka A, Charidemou E, Mylonas C, Michael C, Parekh S, Koufaris C, Skourides P, Papageorgis P, Tessarz P, Kirmizis A. Oncogene. 2022 Jan;41(4):571-585. doi: 10.1038/s41388-021-02113-9. Epub 2021 Nov 16. PubMed
Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity. Menendez D, Anand JR, Murphy CC, Bell WJ, Fu J, Slepushkina N, Buehler E, Martin SE, Lal-Nag M, Nitiss JL, Resnick MA. Oncotarget. 2022 Feb 14;13:332-346. doi: 10.18632/oncotarget.28195. eCollection 2022. PubMed
Signaling Pathway Reporter Screen with SARS-CoV-2 Proteins Identifies nsp5 as a Repressor of p53 Activity. Kumar A, Grams TR, Bloom DC, Toth Z. Viruses. 2022 May 13;14(5). pii: v14051039. doi: 10.3390/v14051039. PubMed
Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. Ueno D, Vasquez JC, Sule A, Liang J, van Doorn J, Sundaram R, Friedman S, Caliliw R, Ohtake S, Bao X, Li J, Ye H, Boyd K, Huang RR, Dodson J, Boutros P, Bindra RS, Shuch B. Oncotarget. 2022 Sep 14;13:1054-1067. doi: 10.18632/oncotarget.28273. eCollection 2022. PubMed
Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors. Cui B, Song L, Wang Q, Li K, He Q, Wu X, Gao F, Liu M, An C, Gao Q, Hu C, Hao X, Dong F, Zhou J, Liu D, Song Z, Yan X, Zhang J, Bai Y, Mao Q, Yang X, Liang Z. Signal Transduct Target Ther. 2023 Sep 25;8(1):366. doi: 10.1038/s41392-023-01603-4. PubMed

If you have published an article using this material, please email us at to have your article added to this page.